WO2023053009 - PYRIDINES AND THEIR USE IN TREATMENT OF GBA-RELATED DISEASES
National phase entry:
Publication Number
WO/2023/053009
Publication Date
06.04.2023
International Application No.
PCT/IB2022/059204
International Filing Date
27.09.2022
Title **
[English]
PYRIDINES AND THEIR USE IN TREATMENT OF GBA-RELATED DISEASES
[French]
PYRIDINES ET LEUR UTILISATION DANS LE TRAITEMENT DE MALADIES ASSOCIÉES AU GBA
Applicants **
ZEVRA DENMARK A/S
Ole Maaløes Vej 3
2200 Copenhagen, DK
Inventors
NEVE, Søren
Ellevænget 4
2800 Lyngby, DK
BROWN, William Dalby
Højtoftevej 12
2860 Søborg, DK
THIRSTRUP, Kenneth
Søborg Parkalle 40
2860 Søborg, DK
Priority Data
21199468.6
28.09.2021
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1207 | |
| EPO | Filing, Examination | 4870 | |
| Japan | Filing | 591 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 2710 |
Total: 9953 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention relates to pyridines and their use for increasing GBA activity and/or levels as well as treatment of GBA-related diseases, such as Parkinson's disease.[French]
La présente invention concerne des pyridines et leur utilisation pour augmenter l'activité et/ou les niveaux de GBA, ainsi que le traitement de maladies associées au GBA, telles que la maladie de Parkinson.